In line with a crucial role of JAK2 in cytokine signal transduction, MPN patients are characterized by high levels of pro-inflammatory cytokines in their circulation, which can be reduced by JAK inhibitor therapy (Verstovsek et al., 2010; Geyer et al., 2015; Mondet et al., 2015). The gene discussed is JAK2; the disease is myeloproliferative disorder.